Khudhair Oula S, Gorial Faiq I, Hameed Ammar F
Baghdad Teaching Hospital, Medicine, Baghdad, Iraq.
Baghdad College of Medicine, University of Baghdad, Medicine, Baghdad, Iraq.
Arch Rheumatol. 2017 Oct 16;33(2):174-180. doi: 10.5606/ArchRheumatol.2018.6524. eCollection 2018 Jun.
This study aims to assess the relationship between fibromyalgia syndrome (FMS) and vitiligo in Iraqi patients and evaluate the predictors of this relationship, if present.
The case-control study included 100 Iraqi patients (46 males, 54 females; mean age 30.4±14 years; range 15 to 65 years) with vitiligo and 200 age- and sex-matched healthy controls (74 males, 126 females; mean age 30.3±9.4 years; range 15 to 62 years). Baseline characteristics of patients and controls were recorded. The 2012 Canadian Guidelines criteria were used for the diagnosis of FMS and applied to all patients and controls.
Prevalence of FMS in vitiligo patients and controls was 12% and 7%, respectively (p=0.15, odds ratio=1.8, 95% confidence interval=0.8-4.08). FMS symptoms in vitiligo patients were fatigue (46%), diffuse body pain (34%), sleep disturbance (33%), cognitive dysfunction (30%), and mood disorders (23%), while visceral involvements were central nervous system (52%), skin (35%), gastrointestinal tract (32%), cardiovascular system- respiratory system (16%), genitourinary tract (8%), and ear nose throat (7%). Of vitiligo patients, FMS was significantly more common among females (22.2%) compared to none among males (0%) (p<0.05). Prevalence of FMS was restricted to female sex only and a significantly higher prevalence rate of FMS was found among female vitiligo patients (22.2%) compared to controls (9.5%). Receiving phototherapy significantly increased the risk of having FMS by 5 times compared to female patients not receiving phototherapy. Use of any steroid reduced the risk of having FMS by 2.5 times (inverse of odds ratio=0.4) among females patients (p>0/05). No significant association was found between FMS in vitiligo patients and age, disease duration, type of vitiligo, use of any immunosuppressant and body mass index (p>0.05).
Fibromyalgia syndrome was more prevalent in vitiligo patients compared to controls, which was clinically important but statistically not significant. There was a significant association between FMS in vitiligo patients and female sex, severe form of vitiligo, and receiving phototherapy. This may suggest that early diagnosis of FMS in vitiligo patients may help in early treatment and subsequently improve patients' quality of life.
本研究旨在评估伊拉克患者中纤维肌痛综合征(FMS)与白癜风之间的关系,并评估这种关系(若存在)的预测因素。
这项病例对照研究纳入了100名伊拉克白癜风患者(46名男性,54名女性;平均年龄30.4±14岁;年龄范围15至65岁)以及200名年龄和性别匹配的健康对照者(74名男性,126名女性;平均年龄30.3±9.4岁;年龄范围15至62岁)。记录了患者和对照者的基线特征。采用2012年加拿大指南标准诊断FMS,并应用于所有患者和对照者。
白癜风患者和对照者中FMS的患病率分别为12%和7%(p = 0.15,优势比 = 1.8,95%置信区间 = 0.8 - 4.08)。白癜风患者的FMS症状包括疲劳(46%)、全身弥漫性疼痛(34%)、睡眠障碍(33%)、认知功能障碍(30%)和情绪障碍(23%),而内脏受累情况为中枢神经系统(52%)、皮肤(35%)、胃肠道(32%)、心血管系统 - 呼吸系统(16%)、泌尿生殖道(8%)和耳鼻喉(7%)。在白癜风患者中,FMS在女性(22.2%)中显著比男性(0%)更常见(p < 0.05)。FMS的患病率仅局限于女性,并且与对照者(9.5%)相比,女性白癜风患者中FMS的患病率显著更高(22.2%)。与未接受光疗的女性患者相比,接受光疗显著增加了患FMS的风险5倍。在女性患者中,使用任何类固醇药物使患FMS的风险降低了2.5倍(优势比的倒数 = 0.4)(p > 0.05)。未发现白癜风患者中的FMS与年龄、病程、白癜风类型、使用任何免疫抑制剂和体重指数之间存在显著关联(p > 故结论:与对照者相比,纤维肌痛综合征在白癜风患者中更普遍,这在临床上具有重要意义,但在统计学上不显著。白癜风患者中的FMS与女性性别、严重型白癜风以及接受光疗之间存在显著关联。这可能表明,白癜风患者中FMS的早期诊断可能有助于早期治疗,进而改善患者的生活质量。